179 related articles for article (PubMed ID: 34808340)
1. A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer.
Middleton G; Robbins H; Andre F; Swanton C
Ann Oncol; 2022 Feb; 33(2):143-157. PubMed ID: 34808340
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. The impact of genomic context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review.
Fulton-Ward T; Middleton G
Ann Oncol; 2023 Dec; 34(12):1113-1130. PubMed ID: 37875224
[TBL] [Abstract][Full Text] [Related]
4. National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH).
Meric-Bernstam F; Ford JM; O'Dwyer PJ; Shapiro GI; McShane LM; Freidlin B; O'Cearbhaill RE; George S; Glade-Bender J; Lyman GH; Tricoli JV; Patton D; Hamilton SR; Gray RJ; Hawkins DS; Ramineni B; Flaherty KT; Grivas P; Yap TA; Berlin J; Doroshow JH; Harris LN; Moscow JA
Clin Cancer Res; 2023 Apr; 29(8):1412-1422. PubMed ID: 36662819
[TBL] [Abstract][Full Text] [Related]
5. The National Lung Matrix Trial of personalized therapy in lung cancer.
Middleton G; Fletcher P; Popat S; Savage J; Summers Y; Greystoke A; Gilligan D; Cave J; O'Rourke N; Brewster A; Toy E; Spicer J; Jain P; Dangoor A; Mackean M; Forster M; Farley A; Wherton D; Mehmi M; Sharpe R; Mills TC; Cerone MA; Yap TA; Watkins TBK; Lim E; Swanton C; Billingham L
Nature; 2020 Jul; 583(7818):807-812. PubMed ID: 32669708
[TBL] [Abstract][Full Text] [Related]
6. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
7. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH.
Coyne GO; Takebe N; Chen AP
Curr Probl Cancer; 2017; 41(3):182-193. PubMed ID: 28372823
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial design in the era of precision medicine.
Fountzilas E; Tsimberidou AM; Vo HH; Kurzrock R
Genome Med; 2022 Aug; 14(1):101. PubMed ID: 36045401
[TBL] [Abstract][Full Text] [Related]
9. An overview of the NCI precision medicine trials-NCI MATCH and MPACT.
Do K; O'Sullivan Coyne G; Chen AP
Chin Clin Oncol; 2015 Sep; 4(3):31. PubMed ID: 26408298
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
11. Utility of comprehensive genomic profiling in directing treatment and improving patient outcomes in advanced non-small cell lung cancer.
Zhao S; Zhang Z; Zhan J; Zhao X; Chen X; Xiao L; Wu K; Ma Y; Li M; Yang Y; Fang W; Zhao H; Zhang L
BMC Med; 2021 Oct; 19(1):223. PubMed ID: 34592968
[TBL] [Abstract][Full Text] [Related]
12. Review of precision cancer medicine: Evolution of the treatment paradigm.
Tsimberidou AM; Fountzilas E; Nikanjam M; Kurzrock R
Cancer Treat Rev; 2020 Jun; 86():102019. PubMed ID: 32251926
[TBL] [Abstract][Full Text] [Related]
13. The New NCI Precision Medicine Trials.
Harris LN; Blanke CD; Erba HP; Ford JM; Gray RJ; LeBlanc ML; Hu-Lieskovan S; Litzow MR; Luger SM; Meric-Bernstam F; O'Dwyer PJ; Othus MKD; Politi K; Shepherd LE; Allegra CJ; Chen HX; Ivy SP; Korde LA; Little RF; McShane LM; Moscow JA; Patton DR; Thurin M; Yee LM; Doroshow JH
Clin Cancer Res; 2023 Dec; 29(23):4728-4732. PubMed ID: 37531248
[TBL] [Abstract][Full Text] [Related]
14. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
[TBL] [Abstract][Full Text] [Related]
15. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
Tsimberidou AM; Iskander NG; Hong DS; Wheler JJ; Falchook GS; Fu S; Piha-Paul S; Naing A; Janku F; Luthra R; Ye Y; Wen S; Berry D; Kurzrock R
Clin Cancer Res; 2012 Nov; 18(22):6373-83. PubMed ID: 22966018
[TBL] [Abstract][Full Text] [Related]
16. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
Kringelbach T; Højgaard M; Rohrberg K; Spanggaard I; Laursen BE; Ladekarl M; Haslund CA; Harsløf L; Belcaid L; Gehl J; Søndergaard L; Eefsen RL; Hansen KH; Kodahl AR; Jensen LH; Holt MI; Oellegaard TH; Yde CW; Ahlborn LB; Lassen U
BMC Cancer; 2023 Feb; 23(1):182. PubMed ID: 36814246
[TBL] [Abstract][Full Text] [Related]
17. A decision support framework for genomically informed investigational cancer therapy.
Meric-Bernstam F; Johnson A; Holla V; Bailey AM; Brusco L; Chen K; Routbort M; Patel KP; Zeng J; Kopetz S; Davies MA; Piha-Paul SA; Hong DS; Eterovic AK; Tsimberidou AM; Broaddus R; Bernstam EV; Shaw KR; Mendelsohn J; Mills GB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25863335
[TBL] [Abstract][Full Text] [Related]
18. Implementing precision cancer medicine in the genomic era.
Chen HZ; Bonneville R; Roychowdhury S
Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
[TBL] [Abstract][Full Text] [Related]
19. The Emergence of Precision Urologic Oncology: A Collaborative Review on Biomarker-driven Therapeutics.
Barbieri CE; Chinnaiyan AM; Lerner SP; Swanton C; Rubin MA
Eur Urol; 2017 Feb; 71(2):237-246. PubMed ID: 27567210
[TBL] [Abstract][Full Text] [Related]
20. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
Bashraheel SS; Domling A; Goda SK
Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]